Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling
about
Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47)GSK-3: Functional Insights from Cell Biology and Animal Models.Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society.Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer.The Role of PI3K/Akt/mTOR Signaling in Gastric Carcinoma.Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks.Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer.miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation.Predicting outcomes in radiation oncology--multifactorial decision support systemsThe Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus.The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.Survival of HER2-Positive Breast Cancer Cells: Receptor Signaling to Apoptotic Control Centers.Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximabSite-specific activation of AKT protects cells from death induced by glucose deprivation.Cell line modeling for systems medicine in cancers (review).Network quantification of EGFR signaling unveils potential for targeted combination therapy.Phosphorylation of SRSF1 by SRPK1 regulates alternative splicing of tumor-related Rac1b in colorectal cells.Runx2 activates PI3K/Akt signaling via mTORC2 regulation in invasive breast cancer cells.Integration of proteomics into systems biology of cancer.Affinity proteomics: the role of specific binding reagents in human proteome analysis.Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.Cancer Systems Biology: a peek into the future of patient care?Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies.Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseasesPBK/TOPK enhances aggressive phenotype in prostate cancer via β-catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion.RPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia.Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer.A novel herbal formula induces cell cycle arrest and apoptosis in association with suppressing the PI3K/AKT pathway in human lung cancer A549 cells.AKT/PKB Signaling: Navigating the Network.Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer.Glycogen synthase kinase-3β positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1.Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment
P2860
Q30412106-35D46F2E-BC34-49E0-943B-7B251D7B77D6Q30472813-BE898B2A-E5B3-4FA4-A6E6-C1998CD872D6Q33399049-A481CA59-D11E-49A3-9D7F-D8575AA197CBQ33602552-13EE61DE-FFCA-4913-A534-E427889228B1Q33850616-C98B917D-E1C5-481D-A4DD-5978B05291DCQ33972424-BD2B7721-2E91-40F5-8274-7D290DA62D56Q34309903-BDF96C6D-9704-4DB3-8FE6-836D566195CAQ34446736-368FE1D7-CE53-4D68-A1AD-38892B4F9046Q35552855-4C72FE77-888C-4802-AE1A-196F8520AB3EQ35897588-5861BF9C-B135-444F-B587-20BDD9A7AB90Q36014711-64BF8BA8-D314-4C51-9B45-BD055E92ECE3Q36161960-E35ABC2C-2F92-474A-8768-1BFC8666E6E2Q36242802-2E6BE259-7030-43D6-BB85-AF0254E6CACAQ37194856-4B8CBCB2-5632-4710-9716-AB0B0F5AFEDCQ37269197-49470772-D784-4C03-9A00-BC2BB2256C79Q37417611-8BADF20F-DBA6-48DA-8493-1F031FEF8A5EQ37503954-1B2C9FAF-EE6E-45E4-A670-56E6B2FBA347Q37660498-C6F55102-9F75-4303-BF8C-84CE211AA5ECQ37661658-1D2B99FD-F84B-4B8E-BFEA-FD322DD5DD98Q37691008-2C9D7076-65B7-4FD9-BA00-FE23A924C54CQ37992554-06125B0B-B052-40BB-B05A-22C496BAE105Q38042457-41EE3C75-CBFB-4DCC-8133-759CA0B30049Q38148747-A2B137C5-9DA1-47E9-88AD-43B04273DCCEQ38184909-2C1CABFD-B89F-4889-8469-BF9DB1333F46Q38249099-A74B4E5C-08E7-4416-AFE8-1CEF6F3BAB13Q38272835-0A43D9DC-06F4-4E7F-AE16-6102E4BD942FQ38386707-77C14942-28F0-438C-A7E4-9A52448E4C56Q38872127-B9F7B6B1-331F-4FC1-8F36-2E2174A8CEEBQ38963132-3B550A35-AA24-40CB-B86B-BA86C00FD9EEQ39084431-257B2A8C-CEF2-4ACE-B9F2-F4DA5EABC452Q39255027-92DB7C07-7740-4DB9-9AA4-5C7F0DC7C3E8Q39325158-4A11EE7A-01FD-4B9F-AA5D-3CCE0F1BCAF1Q39357705-A911696E-3050-4057-A8F9-4AE05BCF38E7Q45735011-6586E0BE-5D12-4B0B-9F2A-F29BFF79876FQ58786537-14F1B89D-AEC4-44A0-8B3B-C09A9E47E497
P2860
Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling
@en
type
label
Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling
@en
prefLabel
Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling
@en
P2093
P2860
P50
P356
P1433
P1476
Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling
@en
P2093
J Donnelly
P2860
P2888
P304
P356
10.1038/ONC.2011.164
P407
P577
2011-06-13T00:00:00Z
P5875
P6179
1011867058